Skip to main content
Log in

Complete Necrosis After Transarterial Chemoembolization Could Predict Prolonged Survival in Patients with Recurrent Intrahepatic Hepatocellular Carcinoma After Curative Resection

Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

We explored the predictors of response to transarterial chemoembolization (TACE) in patients with recurrent intrahepatic hepatocellular carcinoma (HCC) after hepatectomy and investigated the survival of these patients according to the response to TACE.

Methods

We analyzed data from 199 consecutive HCC patients who underwent curative liver resection and who later received repeat TACE for intrahepatic HCC recurrence.

Results

Of 199 patients, 139 (69.8%) achieved complete necrosis (CN) of HCC after repeated TACE (mean TACE session number, 1.3) and the other 60 (30.2%) (non-CN group) did not achieve CN. At hepatectomy, the CN group showed significantly smaller proportions of tumor capsular invasion, microvascular invasion, and pathologic tumor–node–metastasis stage III or IV HCCs. At first TACE, the CN group showed a significantly greater proportion of patients with time to recurrence ≥ 1 year, Child–Pugh class A, serum alpha-fetoprotein (AFP) levels < 200 ng/mL, tumor size < 3 cm, solitary tumors, and nodular tumor types; portal vein invasion were less common than seen in the non-CN group. After multivariate analysis, tumor size < 3 cm and a single tumor at first TACE were independently related to attainment of CN after TACE. Median survival after first TACE was significantly longer in the CN group (48.9 versus 17.0 months). In a Cox regression model, CN after TACE was an independent predictor of favorable survival outcome after first TACE.

Conclusions

CN after repeat TACE for postresection intrahepatic recurrence was attained more commonly in patients with smaller tumor size and lower tumor number at first TACE and favored longer survival in recurrent patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S179–88.

    Article  CAS  PubMed  Google Scholar 

  2. Park KW, Park JW, Choi JI, et al. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol. 2008;23(3):467–73.

    Article  PubMed  Google Scholar 

  3. Esnaola NF, Mirza N, Lauwers GY, et al. Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States, France, and Japan. Ann Surg. 2003;238(5):711–9.

    Article  PubMed  Google Scholar 

  4. Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl. 2005;11(9):1086–92.

    Article  PubMed  Google Scholar 

  5. Cha C, Fong Y, Jarnagin WR, et al. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg. 2003;197(5):753–8.

    Article  PubMed  Google Scholar 

  6. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25(2):181–200.

    Article  PubMed  Google Scholar 

  7. Shah SA, Greig PD, Gallinger S, et al. Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg. 2006;202(2):275–83.

    Article  PubMed  Google Scholar 

  8. Poon RT, Fan ST, O’Suilleabhain CB, Wong J. Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy. J Am Coll Surg. 2002;195(3):311–8.

    Article  PubMed  Google Scholar 

  9. Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg. 2003;238(5):703–10.

    Article  PubMed  Google Scholar 

  10. Poon RT, Fan ST, Lo CM, et al. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg. 1999;229(2):216–22.

    Article  CAS  PubMed  Google Scholar 

  11. Shimada M, Saitoh A, Kano T, et al. The effect of a perioperative steroid pulse on surgical stress in hepatic resection. Int Surg. 1996;81(1):49–51.

    CAS  PubMed  Google Scholar 

  12. Shimada K, Sakamoto Y, Esaki M, et al. Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma. Ann Surg Oncol. 2007;14(8):2337–47.

    Article  PubMed  Google Scholar 

  13. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–76.

    Article  CAS  PubMed  Google Scholar 

  14. Lee PH, Lin WJ, Tsang YM, et al. Clinical management of recurrent hepatocellular carcinoma. Ann Surg. 1995;222(5):670–6.

    Article  CAS  PubMed  Google Scholar 

  15. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37(2):429–42.

    Article  CAS  PubMed  Google Scholar 

  16. Shim JH, Park JW, Choi JI, et al. Does postembolization fever after chemoembolization have prognostic significance for survival in patients with unresectable hepatocellular carcinoma? J Vasc Interv Radiol. 2009;20(2):209–16.

    Article  PubMed  Google Scholar 

  17. Han K, Lee J, Seong J. Treatment of non-resectable hepatocellular carcinoma. J Gastroenterol Hepatol. 2002;17 Suppl 3:S424–7.

    Article  PubMed  Google Scholar 

  18. Yu JS, Kim KW, Sung KB, et al. Small arterial-portal venous shunts: a cause of pseudolesions at hepatic imaging. Radiology. 1997;203(3):737–42.

    CAS  PubMed  Google Scholar 

  19. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–36.

    Article  PubMed  Google Scholar 

  20. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–9.

    Article  CAS  PubMed  Google Scholar 

  21. Jang MK, Lee HC, Kim IS, et al. Role of additional angiography and chemoembolization in patients with hepatocellular carcinoma who achieved complete necrosis following transarterial chemoembolization. J Gastroenterol Hepatol. 2004;19(9):1074–80.

    Article  PubMed  Google Scholar 

  22. Park JW. [Practice guideline for diagnosis and treatment of hepatocellular carcinoma]. Korean J Hepatol. 2004;10(2):88–98.

    PubMed  Google Scholar 

  23. Sobin LH, Wittekind Ch, eds. TMN classification of malignat tumors, 5th ed. New York: Wiley;1997.

    Google Scholar 

  24. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232(1):10–24.

    Article  CAS  PubMed  Google Scholar 

  25. Choi GH, Kim DH, Kang CM, et al. Prognostic factors and optimal treatment strategy for intrahepatic nodular recurrence after curative resection of hepatocellular carcinoma. Ann Surg Oncol. 2008;15(2):618–29.

    Article  PubMed  Google Scholar 

  26. Poon RT, Ngan H, Lo CM, et al. Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. J Surg Oncol. 2000;73(2):109–14.

    Article  CAS  PubMed  Google Scholar 

  27. Okazaki M, Yamasaki S, Ono H, et al. Chemoembolotherapy for recurrent hepatocellular carcinoma in the residual liver after hepatectomy. Hepatogastroenterology. 1993;40(4):320–3.

    CAS  PubMed  Google Scholar 

  28. Ouchi K, Matsubara S, Fukuhara K, et al. Recurrence of hepatocellular carcinoma in the liver remnant after hepatic resection. Am J Surg. 1993;166(3):270–3.

    Article  CAS  PubMed  Google Scholar 

  29. Takayasu K, Arii S, Matsuo N, et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR Am J Roentgenol. 2000;175(3):699–704.

    CAS  PubMed  Google Scholar 

  30. Choi BI, Kim HC, Han JK, et al. Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathologic findings. Radiology. 1992;182(3):709–13.

    CAS  PubMed  Google Scholar 

  31. Taura K, Ikai I, Hatano E, et al. Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: an analysis of 610 patients over 16 years old. Ann Surg. 2006;244(2):265–73.

    Article  PubMed  Google Scholar 

  32. Takayasu K, Wakao F, Moriyama N, et al. Postresection recurrence of hepatocellular carcinoma treated by arterial embolization: analysis of prognostic factors. Hepatology. 1992;16(4):906–11.

    Article  CAS  PubMed  Google Scholar 

  33. Jinno K, Moriwaki S, Tanada M, et al. Clinicopathological study on combination therapy consisting of arterial infusion of lipiodol-dissolved SMANCS and transcatheter arterial embolization for hepatocellular carcinoma. Cancer Chemother Pharmacol. 1992;31 Suppl:S7–12.

    Article  PubMed  Google Scholar 

  34. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35(3):421–30.

    Google Scholar 

  35. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Liver Cancer Study Group of Japan. Ann Surg. 1990;211(3):277–87.

    Google Scholar 

  36. Ernst O, Sergent G, Mizrahi D, et al. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response. AJR Am J Roentgenol. 1999;172(1):59–64.

    CAS  PubMed  Google Scholar 

  37. Tanaka K, Inoue S, Numata K, et al. Color Doppler sonography of hepatocellular carcinoma before and after treatment by transcatheter arterial embolization. AJR Am J Roentgenol. 1992;158(3):541–6.

    CAS  PubMed  Google Scholar 

  38. Lee JK, Chung YH, Song BC, et al. Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization. J Gastroenterol Hepatol. 2002;17(1):52–8.

    Article  PubMed  Google Scholar 

  39. Bismuth H, Morino M, Sherlock D, et al. Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg. 1992;163(4):387–94.

    Article  CAS  PubMed  Google Scholar 

  40. Huang YS, Chiang JH, Wu JC, et al. Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test. Am J Gastroenterol. 2002;97(5):1223–7.

    Article  PubMed  Google Scholar 

  41. Cheng BQ, Jia CQ, Liu CT, et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA. 2008;299(14):1669–77.

    Article  CAS  PubMed  Google Scholar 

  42. Ishii H, Okada S, Sato T, et al. Effect of percutaneous ethanol injection for postoperative recurrence of hepatocellular carcinoma in combination with transcatheter arterial embolization. Hepatogastroenterology. 1996;43(9):644–50.

    CAS  PubMed  Google Scholar 

  43. Sato M, Watanabe Y, Iseki N, et al. Chemoembolization and percutaneous ethanol injection for intrahepatic recurrence of hepatocellular carcinoma after hepatic resection. Hepatogastroenterology. 1996;43(12):1421–6.

    CAS  PubMed  Google Scholar 

  44. Choi BO, Choi IB, Jang HS, et al. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer 2008;8:351.

    Article  PubMed  Google Scholar 

  45. Yamada K, Izaki K, Sugimoto K, et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2003;57(1):113–9.

    PubMed  Google Scholar 

  46. Poon RT, Fan ST, Ng IO, et al. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000;89(3):500–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Young-Joo Lee MD.

Additional information

Ju Hyun Shim and Kang Mo Kim are share the first authorship of this article.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shim, J.H., Kim, K.M., Lee, YJ. et al. Complete Necrosis After Transarterial Chemoembolization Could Predict Prolonged Survival in Patients with Recurrent Intrahepatic Hepatocellular Carcinoma After Curative Resection. Ann Surg Oncol 17, 869–877 (2010). https://doi.org/10.1245/s10434-009-0788-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-009-0788-7

Keywords

Navigation